Literature DB >> 9203642

Binding of a thrombin receptor tethered ligand analogue to human platelet thrombin receptor.

H S Ahn1, C Foster, G Boykow, L Arik, A Smith-Torhan, D Hesk, M Chatterjee.   

Abstract

A thrombin receptor-radioligand binding assay was developed using [3H]A(pF-F)R(ChA)(hR)Y-NH2 ([3H]haTRAP), a high affinity thrombin receptor-activating peptide (TRAP), and human platelet membranes. Scatchard analysis of saturation binding data indicated that [3H]haTRAP bound to platelet membranes with a Kd of 15 nM and a Bmax of 5.2 pmol/mg of protein. The binding was reduced by GPPNHP, a nonmetabolizable GTP analogue. Various TRAPs and a TRAP antagonist, but not other receptor agonists, displaced [3H]haTRAP from the binding sites. SFLLRN-NH2, a thrombin receptor-tethered ligand analogue, and [3H]haTRAP exhibited competitive binding for the same binding sites. The relative affinity of these peptides for the binding site paralleled their EC50 or IC50 values for platelet aggregation. These data indicate that [3H]haTRAP binds specifically and saturably to the functioning G protein-linked thrombin (tethered ligand) receptor in human platelet membranes.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9203642     DOI: 10.1124/mol.51.2.350

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  7 in total

1.  The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

2.  Himbacine-derived thrombin receptor antagonists: c7-spirocyclic analogues of vorapaxar.

Authors:  Mariappan V Chelliah; Keith Eagen; Zhuyan Guo; Samuel Chackalamannil; Yan Xia; Hsingan Tsai; William J Greenlee; Ho-Sam Ahn; Stan Kurowski; George Boykow; Yunsheng Hsieh; Madhu Chintala
Journal:  ACS Med Chem Lett       Date:  2014-03-11       Impact factor: 4.345

3.  Binding of a highly potent protease-activated receptor-2 (PAR2) activating peptide, [3H]2-furoyl-LIGRL-NH2, to human PAR2.

Authors:  Toru Kanke; Hiroyuki Ishiwata; Mototsugu Kabeya; Masako Saka; Takeshi Doi; Yukio Hattori; Atsufumi Kawabata; Robin Plevin
Journal:  Br J Pharmacol       Date:  2005-05       Impact factor: 8.739

4.  Himbacine-derived thrombin receptor antagonists: c7-aminomethyl and c9a-hydroxy analogues of vorapaxar.

Authors:  Mariappan V Chelliah; Samuel Chackalamannil; Yan Xia; William J Greenlee; Ho-Sam Ahn; Stan Kurowski; George Boykow; Yunsheng Hsieh; Madhu Chintala
Journal:  ACS Med Chem Lett       Date:  2013-12-18       Impact factor: 4.345

5.  A secreted tyrosine kinase acts in the extracellular environment.

Authors:  Mattia R Bordoli; Jina Yum; Susanne B Breitkopf; Jonathan N Thon; Joseph E Italiano; Junyu Xiao; Carolyn Worby; Swee-Kee Wong; Grace Lin; Maja Edenius; Tracy L Keller; John M Asara; Jack E Dixon; Chang-Yeol Yeo; Malcolm Whitman
Journal:  Cell       Date:  2014-08-28       Impact factor: 41.582

6.  Protease-activated receptor-4 uses dual prolines and an anionic retention motif for thrombin recognition and cleavage.

Authors:  Suzanne L Jacques; Athan Kuliopulos
Journal:  Biochem J       Date:  2003-12-15       Impact factor: 3.857

7.  Unproductive cleavage and the inactivation of protease-activated receptor-1 by trypsin in vascular endothelial cells.

Authors:  Tetsuzo Nakayama; Katsuya Hirano; Yoshinobu Shintani; Junji Nishimura; Akio Nakatsuka; Hirotaka Kuga; Shosuke Takahashi; Hideo Kanaide
Journal:  Br J Pharmacol       Date:  2003-01       Impact factor: 8.739

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.